Long-term health follow-up of Chinese people with myotonic dystrophy type 1
Tracks how myotonic dystrophy type 1 affects Chinese patients' health.
Key facts
- Who runs it
- Huashan Hospital
- Where
- China22 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Chinese Multicenter Clinical Outcome Cohort Study of Myotonic Dystrophy Type 1 (C-DMCOS-DM1)
- Status
- Enrolling by invitation
- People taking part
- 1,000 people, planned
- Started
- 1 Aug 2021
- Expected to end
- 30 Dec 2035
- Type of study
- Observational
- Treatments tested
- MRI scan
- Electrocardiography
- Pulmonary function test
- Electrocardiography and 24-hour Holter monitoring
- Skeletal muscle biopsy (residual specimen)
- Wearable-device continuous physiological monitoring
- Video and voice recording for AI analysis
- Record updated
- 2 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for Chinese people with myotonic dystrophy type 1 (DM1), confirmed by a genetic test. It follows them over time and does not test a new treatment.
- Age
- The record gives no age limits. Minors can join with consent signed by a legal guardian.
- Sex
- All sexes can join.
- Disease stage
- Myotonic dystrophy type 1 confirmed by a genetic test.
- Biomarker or test result
- CTG repeat expansion in the 3' untranslated region of the DMPK gene.
Main reasons for not taking part
- Pregnancy, because of MRI safety
- Unable to follow the study procedures
- Unable to give informed consent, or the guardian says no
- A severe, unstable medical condition that prevents the study tests
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Genetically confirmed DM1 (CTG repeat expansion in the 3' untranslated region of the DMPK gene)
- Any sex
- Able to attend regular follow-up and willing to provide and store residual blood, urine, and other biospecimens for research
- Voluntary participation with signed informed consent (signed by legal guardian for minors)
- Consent to use of routine clinical, examination, and follow-up data for research
Who cannot take part
- Severe, unstable medical condition that precludes assessments
- Unable to comply with study procedures
- Unable to provide informed consent, or guardian declines participation
- Pregnancy (for MRI safety)
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Myotonic dystrophy type 1 (DM1) is an autosomal dominant multisystem disorder caused by an expanded CTG trinucleotide repeat in the 3' untranslated region of the DMPK gene. Beyond myotonia and progressive skeletal muscle weakness, DM1 involves the cardiac, respiratory, central nervous, gastrointestinal, endocrine, and ocular systems, and respiratory and cardiac involvement are the leading causes of disability and death. Systematic, long-term outcome data in Chinese DM1 patients are lacking.
Read full original descriptionShow less
C-DMCOS-DM1 is a multicenter, prospective, observational cohort study that systematically records demographic data, multisystem involvement, and predefined disability-related clinical outcome events in genetically confirmed Chinese DM1 patients, with regular follow-up every 3 to 6 months. The study also collects residual blood, skeletal muscle, myocardium (when a pacemaker is implanted), and urine specimens for transcriptomic and other molecular studies. The aims are to characterize the disease burden of Chinese DM1 patients, identify risk and prognostic factors for disabling outcomes, and build risk-prediction models to inform follow-up, management, and future clinical trials.
The group in the trial
- DM1 patients
Patient cohort
Treatment: MRI scan, Electrocardiography, Pulmonary function test, Electrocardiography and 24-hour Holter monitoring, Skeletal muscle biopsy (residual specimen), Wearable-device continuous physiological monitoring, and Video and voice recording for AI analysis
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Multicenter, Prospective, Observational Cohort Study of Multi-System Involvement and Disability-Related Clinical Outcomes in Chinese Patients With Myotonic Dystrophy Type 1 (C-DMCOS-DM1)
- Plain-language title
- Long-term health follow-up of Chinese people with myotonic dystrophy type 1Generated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 2 June 2026